NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Dave Innes
Vice President, Investor Relations
NW Bio?

Highlights Of NW Bio’s Program Update
In The Industry Expert Theater Presentation At ASCO

For immediate release on Tuesday, June 4, 2019

Follow-up survival data from the Information Arm patients who did not qualify for the Phase III trial are encouraging and appear consistent with the blinded interim data from the trial.

In the group of 25 Information Arm patients who had actual or apparent early tumor recurrence, the follow-up data showed that 40% of the patients lived for 3 years or more, 20% of the patients lived for 5 years or more, and 12% of the patients are still alive at 7 years.

This Information Arm survival data is especially encouraging since this group included patients who already had actual tumor recurrence as well as others who had the appearance of tumor recurrence but who could not be definitely determined.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149193678

19 NOV 2018
Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma
Presented at Society for Neuro-Oncology Conference

https://nwbio.com/updated-interim-data-from-phase-3-trial-of-dcvax-l-for-glioblastoma/

The top 100 patients – 30% of all patients in the trial – have a Kaplan Meier median survival of 58.4 months.

My conclusion: the survival data appear consistent with the blinded interim data of the trial. All the numbers they gave us in the past were based on the ITT group = 331 patients.
So,

data NOV 2018::
50 patients are expected to live for 58.4 months or more.

data JUNE 2019
66 patients (20% of the blinded ITT group= 331 patients) are expected to live for 60 months or more!

That is a 32% improvement!